Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Survival and failure types after radiation therapy of vulvar cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Individualized estimates of overall survival in radiation therapy plan optimization - A concept study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Line Bjerregaard Stick
  • Ebbe Laugaard Lorenzen
  • Esben Svitzer Yates
  • Carmel Anandadas
  • Karen Andersen
  • Cynthia Aristei
  • Orla Byrne
  • Sandra Hol
  • Ingelise Jensen
  • Anna M. Kirby
  • Youlia M. Kirova
  • Livia Marrazzo
  • Angela Matías-Pérez
  • Mette Marie Bruun Nielsen
  • Henrik Dahl Nissen
  • Sileida Oliveros
  • Karolien Verhoeven
  • Johan Vikström
  • Birgitte Vrou Offersen
View graph of relations

Background and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial. Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose–response relationships for heart and lung. Results: Median mean heart dose was 3.0 Gy (range, 1.1–8.2 Gy) for left-sided and 1.4 Gy (0.4–11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9–57%). The DBCG Radiotherapy Committee chose mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37% as thresholds for inclusion in the randomised trial. Using these thresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial. Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37%.

Original languageEnglish
JournalClinical and Translational Radiation Oncology
Volume27
Pages (from-to)126-131
Number of pages6
ISSN2405-6308
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

    Research areas

  • Breast cancer, Heart and lung exposure, Patient selection, Proton therapy

ID: 75619681